DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects

Phase 1

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: placebo
Drug: NNC0165-1562

First Posted Date: 2015-10-05

Last Posted Date: 2018-07-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 93

Registration Number: NCT02568306

Locations: 🇺🇸
Novo Nordisk Investigational Site, Tempe, Arizona, United States

Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: Faster-acting insulin aspart
Drug: insulin aspart

First Posted Date: 2015-10-05

Last Posted Date: 2018-12-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 42

Registration Number: NCT02568280

Locations: 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria

Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: semaglutide
Drug: placebo

First Posted Date: 2015-09-23

Last Posted Date: 2017-01-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 113

Registration Number: NCT02557620

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial

Phase 2

Completed

Conditions: Haemophilia A With Inhibitors
Congenital Bleeding Disorder
Haemophilia B With Inhibitors

Interventions: Other: No treatment given

First Posted Date: 2015-09-04

Last Posted Date: 2019-01-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 19

Registration Number: NCT02541942

Locations: 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand

Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec
Drug: insulin glargine

First Posted Date: 2015-09-01

Last Posted Date: 2019-05-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 60

Registration Number: NCT02536859

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

Phase 3

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: placebo
Drug: liraglutide

First Posted Date: 2015-08-18

Last Posted Date: 2023-07-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 56

Registration Number: NCT02527200

Locations: 🇹🇷
Novo Nordisk Investigational Site, Trabzon, Turkey

A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide

First Posted Date: 2015-07-22

Last Posted Date: 2018-09-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 635

Registration Number: NCT02505334

Locations: 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: insulin glargine
Drug: insulin degludec/liraglutide

First Posted Date: 2015-07-17

Last Posted Date: 2019-11-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1012

Registration Number: NCT02501161

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wolverhampton, United Kingdom

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin aspart
Drug: Faster-acting insulin aspart
Drug: insulin degludec

First Posted Date: 2015-07-16

Last Posted Date: 2019-06-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1108

Registration Number: NCT02500706

Locations: 🇨🇳
Novo Nordisk Investigational Site, Taoyuan, Taiwan

Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: placebo
Drug: Concizumab

First Posted Date: 2015-07-07

Last Posted Date: 2017-07-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT02490787

Locations: 🇬🇧
Novo Nordisk Investigational Site, Southampton, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy